                         SEQUENCE LISTING

<110>  Fundacin Centro Nacional de Investigaciones 
       Cardiovasculares Carlos III
 
<120>  Inhibitors of Membrane-type 4 matrix metalloproteinase (MT4-MMP) 
       and its use in the treatment of diseases benefiting from an 
       increase in the activity of patrolling monocytes

<130>  903 610

<150>  EP 17 382 735.3
<151>  2017-11-03

<160>  160   

<170>  PatentIn version 3.5

<210>  1
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MT4-MMP WT forward  primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  1
tcagacacag ccagatcagg                                                   20


<210>  2
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MT4-MMP  KO forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  2
aatatgcgaa gtggacctgg                                                   20


<210>  3
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MT4-MMP reverse primer (common to WT and KO)


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  3
agcaacacgg catccactac                                                   20


<210>  4
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Itgam forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  4
gctgaaagct ctccacctca                                                   20


<210>  5
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Itgam reverse primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  5
aggccacagg tattttgtcg                                                   20


<210>  6
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mmp17 forward primer


<220>
<221>  misc_feature
<222>  (1)..(21)

<400>  6
actgtccaaa gcgattactg c                                                 21


<210>  7
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mmp17 reverse primer


<220>
<221>  misc_feature
<222>  (1)..(21)

<400>  7
gcatcgaggg gttttcatca g                                                 21


<210>  8
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  IL6 forward primer


<220>
<221>  misc_feature
<222>  (1)..(23)

<400>  8
tagtccttcc taccccaatt tcc                                               23


<210>  9
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  IL6 reverse primer


<220>
<221>  misc_feature
<222>  (1)..(21)

<400>  9
ttggtcctta gccactcctt c                                                 21


<210>  10
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tnfa forward primer


<220>
<221>  misc_feature
<222>  (1)..(21)

<400>  10
ccagaccctc acactcagat c                                                 21


<210>  11
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tnfa reverse primer


<220>
<221>  misc_feature
<222>  (1)..(21)

<400>  11
cacttggtgg tttgctacga c                                                 21


<210>  12
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  IL1b forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  12
gctgaaagct ctccacctca                                                   20


<210>  13
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  IL1b reverse primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  13
aggccacagg tattttgtcg                                                   20


<210>  14
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  IL10 forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  14
tgaattccct gggtgagaag                                                   20


<210>  15
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  IL10 reverse primer


<220>
<221>  misc_feature
<222>  (1)..(21)

<400>  15
tcactcttca cctgctccac t                                                 21


<210>  16
<211>  19
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tgfb forward primer


<220>
<221>  misc_feature
<222>  (1)..(19)

<400>  16
gctaatggtg gaccgcaac                                                    19


<210>  17
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tgfb reverse primer


<220>
<221>  misc_feature
<222>  (1)..(23)

<400>  17
cgaatgtctg acgtattgaa gaa                                               23


<210>  18
<211>  19
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mafb forward primer


<220>
<221>  misc_feature
<222>  (1)..(19)

<400>  18
aggaccgctt ctctgatga                                                    19


<210>  19
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mafb reverse primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  19
gagctgcgtc ttctcgttct                                                   20


<210>  20
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Cd5l forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  20
ggaagacacg ttggctcaat                                                   20


<210>  21
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Cd5l reverse primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  21
agacgcacat cctctggaat                                                   20


<210>  22
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Cd36 forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  22
gagcaactgg tggatggttt                                                   20


<210>  23
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Cd36 reverse primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  23
gcagaatcaa gggagagcac                                                   20


<210>  24
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Ccr5 forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  24
tgcagtcctc attttccaca                                                   20


<210>  25
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Ccr5 reverse primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  25
cctacagcga aacagggtgt                                                   20


<210>  26
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Ccr2 forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  26
acaccctgtt tcgctgtagg                                                   20


<210>  27
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Ccr2 reverse primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  27
cctggaaggt ggtcaagaag                                                   20


<210>  28
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Cx3Cr1 forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  28
aagttccctt cccatctgct                                                   20


<210>  29
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Cx3Cr1 reverse primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  29
aagttccctt cccatctgct                                                   20


<210>  30
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  cyclophilin forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  30
acaggtcctg gcatcttgtc                                                   20


<210>  31
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  cyclophilin reverse primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  31
catggcttcc acaatgttca                                                   20


<210>  32
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  36b4 forward primer


<220>
<221>  misc_feature
<222>  (1)..(20)

<400>  32
gcgacctgga agtccaacta                                                   20


<210>  33
<211>  19
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  36b4 reverse primer


<220>
<221>  misc_feature
<222>  (1)..(19)

<400>  33
atctgctgca tctgcttgg                                                    19


<210>  34
<211>  440
<212>  PRT
<213>  Homo sapiens


<220>
<221>  CHAIN
<222>  (1)..(440)
<223>  mature human MT4-MMP; positions 126 to 565 of Uniprot ID Q9ULZ9.4

<400>  34

Gln Ala Pro Ala Pro Thr Lys Trp Asn Lys Arg Asn Leu Ser Trp Arg 
1               5                   10                  15      


Val Arg Thr Phe Pro Arg Asp Ser Pro Leu Gly His Asp Thr Val Arg 
            20                  25                  30          


Ala Leu Met Tyr Tyr Ala Leu Lys Val Trp Ser Asp Ile Ala Pro Leu 
        35                  40                  45              


Asn Phe His Glu Val Ala Gly Ser Ala Ala Asp Ile Gln Ile Asp Phe 
    50                  55                  60                  


Ser Lys Ala Asp His Asn Asp Gly Tyr Pro Phe Asp Gly Pro Gly Gly 
65                  70                  75                  80  


Thr Val Ala His Ala Phe Phe Pro Gly His His His Thr Ala Gly Asp 
                85                  90                  95      


Thr His Phe Asp Asp Asp Glu Ala Trp Thr Phe Arg Ser Ser Asp Ala 
            100                 105                 110         


His Gly Met Asp Leu Phe Ala Val Ala Val His Glu Phe Gly His Ala 
        115                 120                 125             


Ile Gly Leu Ser His Val Ala Ala Ala His Ser Ile Met Arg Pro Tyr 
    130                 135                 140                 


Tyr Gln Gly Pro Val Gly Asp Pro Leu Arg Tyr Gly Leu Pro Tyr Glu 
145                 150                 155                 160 


Asp Lys Val Arg Val Trp Gln Leu Tyr Gly Val Arg Glu Ser Val Ser 
                165                 170                 175     


Pro Thr Ala Gln Pro Glu Glu Pro Pro Leu Leu Pro Glu Pro Pro Asp 
            180                 185                 190         


Asn Arg Ser Ser Ala Pro Pro Arg Lys Asp Val Pro His Arg Cys Ser 
        195                 200                 205             


Thr His Phe Asp Ala Val Ala Gln Ile Arg Gly Glu Ala Phe Phe Phe 
    210                 215                 220                 


Lys Gly Lys Tyr Phe Trp Arg Leu Thr Arg Asp Arg His Leu Val Ser 
225                 230                 235                 240 


Leu Gln Pro Ala Gln Met His Arg Phe Trp Arg Gly Leu Pro Leu His 
                245                 250                 255     


Leu Asp Ser Val Asp Ala Val Tyr Glu Arg Thr Ser Asp His Lys Ile 
            260                 265                 270         


Val Phe Phe Lys Gly Asp Arg Tyr Trp Val Phe Lys Asp Asn Asn Val 
        275                 280                 285             


Glu Glu Gly Tyr Pro Arg Pro Val Ser Asp Phe Ser Leu Pro Pro Gly 
    290                 295                 300                 


Gly Ile Asp Ala Ala Phe Ser Trp Ala His Asn Asp Arg Thr Tyr Phe 
305                 310                 315                 320 


Phe Lys Asp Gln Leu Tyr Trp Arg Tyr Asp Asp His Thr Arg His Met 
                325                 330                 335     


Asp Pro Gly Tyr Pro Ala Gln Ser Pro Leu Trp Arg Gly Val Pro Ser 
            340                 345                 350         


Thr Leu Asp Asp Ala Met Arg Trp Ser Asp Gly Ala Ser Tyr Phe Phe 
        355                 360                 365             


Arg Gly Gln Glu Tyr Trp Lys Val Leu Asp Gly Glu Leu Glu Val Ala 
    370                 375                 380                 


Pro Gly Tyr Pro Gln Ser Thr Ala Arg Asp Trp Leu Val Cys Gly Asp 
385                 390                 395                 400 


Ser Gln Ala Asp Gly Ser Val Ala Ala Gly Val Asp Ala Ala Glu Gly 
                405                 410                 415     


Pro Arg Ala Pro Pro Gly Gln His Asp Gln Ser Arg Ser Glu Asp Gly 
            420                 425                 430         


Tyr Glu Val Cys Ser Cys Thr Ser 
        435                 440 


<210>  35
<211>  1136
<212>  PRT
<213>  Homo sapiens


<220>
<221>  CHAIN
<222>  (1)..(1136)
<223>  Human Itgam; positions  17 to 1152 of Uniprot ID P11215.2

<400>  35

Phe Asn Leu Asp Thr Glu Asn Ala Met Thr Phe Gln Glu Asn Ala Arg 
1               5                   10                  15      


Gly Phe Gly Gln Ser Val Val Gln Leu Gln Gly Ser Arg Val Val Val 
            20                  25                  30          


Gly Ala Pro Gln Glu Ile Val Ala Ala Asn Gln Arg Gly Ser Leu Tyr 
        35                  40                  45              


Gln Cys Asp Tyr Ser Thr Gly Ser Cys Glu Pro Ile Arg Leu Gln Val 
    50                  55                  60                  


Pro Val Glu Ala Val Asn Met Ser Leu Gly Leu Ser Leu Ala Ala Thr 
65                  70                  75                  80  


Thr Ser Pro Pro Gln Leu Leu Ala Cys Gly Pro Thr Val His Gln Thr 
                85                  90                  95      


Cys Ser Glu Asn Thr Tyr Val Lys Gly Leu Cys Phe Leu Phe Gly Ser 
            100                 105                 110         


Asn Leu Arg Gln Gln Pro Gln Lys Phe Pro Glu Ala Leu Arg Gly Cys 
        115                 120                 125             


Pro Gln Glu Asp Ser Asp Ile Ala Phe Leu Ile Asp Gly Ser Gly Ser 
    130                 135                 140                 


Ile Ile Pro His Asp Phe Arg Arg Met Lys Glu Phe Val Ser Thr Val 
145                 150                 155                 160 


Met Glu Gln Leu Lys Lys Ser Lys Thr Leu Phe Ser Leu Met Gln Tyr 
                165                 170                 175     


Ser Glu Glu Phe Arg Ile His Phe Thr Phe Lys Glu Phe Gln Asn Asn 
            180                 185                 190         


Pro Asn Pro Arg Ser Leu Val Lys Pro Ile Thr Gln Leu Leu Gly Arg 
        195                 200                 205             


Thr His Thr Ala Thr Gly Ile Arg Lys Val Val Arg Glu Leu Phe Asn 
    210                 215                 220                 


Ile Thr Asn Gly Ala Arg Lys Asn Ala Phe Lys Ile Leu Val Val Ile 
225                 230                 235                 240 


Thr Asp Gly Glu Lys Phe Gly Asp Pro Leu Gly Tyr Glu Asp Val Ile 
                245                 250                 255     


Pro Glu Ala Asp Arg Glu Gly Val Ile Arg Tyr Val Ile Gly Val Gly 
            260                 265                 270         


Asp Ala Phe Arg Ser Glu Lys Ser Arg Gln Glu Leu Asn Thr Ile Ala 
        275                 280                 285             


Ser Lys Pro Pro Arg Asp His Val Phe Gln Val Asn Asn Phe Glu Ala 
    290                 295                 300                 


Leu Lys Thr Ile Gln Asn Gln Leu Arg Glu Lys Ile Phe Ala Ile Glu 
305                 310                 315                 320 


Gly Thr Gln Thr Gly Ser Ser Ser Ser Phe Glu His Glu Met Ser Gln 
                325                 330                 335     


Glu Gly Phe Ser Ala Ala Ile Thr Ser Asn Gly Pro Leu Leu Ser Thr 
            340                 345                 350         


Val Gly Ser Tyr Asp Trp Ala Gly Gly Val Phe Leu Tyr Thr Ser Lys 
        355                 360                 365             


Glu Lys Ser Thr Phe Ile Asn Met Thr Arg Val Asp Ser Asp Met Asn 
    370                 375                 380                 


Asp Ala Tyr Leu Gly Tyr Ala Ala Ala Ile Ile Leu Arg Asn Arg Val 
385                 390                 395                 400 


Gln Ser Leu Val Leu Gly Ala Pro Arg Tyr Gln His Ile Gly Leu Val 
                405                 410                 415     


Ala Met Phe Arg Gln Asn Thr Gly Met Trp Glu Ser Asn Ala Asn Val 
            420                 425                 430         


Lys Gly Thr Gln Ile Gly Ala Tyr Phe Gly Ala Ser Leu Cys Ser Val 
        435                 440                 445             


Asp Val Asp Ser Asn Gly Ser Thr Asp Leu Val Leu Ile Gly Ala Pro 
    450                 455                 460                 


His Tyr Tyr Glu Gln Thr Arg Gly Gly Gln Val Ser Val Cys Pro Leu 
465                 470                 475                 480 


Pro Arg Gly Arg Ala Arg Trp Gln Cys Asp Ala Val Leu Tyr Gly Glu 
                485                 490                 495     


Gln Gly Gln Pro Trp Gly Arg Phe Gly Ala Ala Leu Thr Val Leu Gly 
            500                 505                 510         


Asp Val Asn Gly Asp Lys Leu Thr Asp Val Ala Ile Gly Ala Pro Gly 
        515                 520                 525             


Glu Glu Asp Asn Arg Gly Ala Val Tyr Leu Phe His Gly Thr Ser Gly 
    530                 535                 540                 


Ser Gly Ile Ser Pro Ser His Ser Gln Arg Ile Ala Gly Ser Lys Leu 
545                 550                 555                 560 


Ser Pro Arg Leu Gln Tyr Phe Gly Gln Ser Leu Ser Gly Gly Gln Asp 
                565                 570                 575     


Leu Thr Met Asp Gly Leu Val Asp Leu Thr Val Gly Ala Gln Gly His 
            580                 585                 590         


Val Leu Leu Leu Arg Ser Gln Pro Val Leu Arg Val Lys Ala Ile Met 
        595                 600                 605             


Glu Phe Asn Pro Arg Glu Val Ala Arg Asn Val Phe Glu Cys Asn Asp 
    610                 615                 620                 


Gln Val Val Lys Gly Lys Glu Ala Gly Glu Val Arg Val Cys Leu His 
625                 630                 635                 640 


Val Gln Lys Ser Thr Arg Asp Arg Leu Arg Glu Gly Gln Ile Gln Ser 
                645                 650                 655     


Val Val Thr Tyr Asp Leu Ala Leu Asp Ser Gly Arg Pro His Ser Arg 
            660                 665                 670         


Ala Val Phe Asn Glu Thr Lys Asn Ser Thr Arg Arg Gln Thr Gln Val 
        675                 680                 685             


Leu Gly Leu Thr Gln Thr Cys Glu Thr Leu Lys Leu Gln Leu Pro Asn 
    690                 695                 700                 


Cys Ile Glu Asp Pro Val Ser Pro Ile Val Leu Arg Leu Asn Phe Ser 
705                 710                 715                 720 


Leu Val Gly Thr Pro Leu Ser Ala Phe Gly Asn Leu Arg Pro Val Leu 
                725                 730                 735     


Ala Glu Asp Ala Gln Arg Leu Phe Thr Ala Leu Phe Pro Phe Glu Lys 
            740                 745                 750         


Asn Cys Gly Asn Asp Asn Ile Cys Gln Asp Asp Leu Ser Ile Thr Phe 
        755                 760                 765             


Ser Phe Met Ser Leu Asp Cys Leu Val Val Gly Gly Pro Arg Glu Phe 
    770                 775                 780                 


Asn Val Thr Val Thr Val Arg Asn Asp Gly Glu Asp Ser Tyr Arg Thr 
785                 790                 795                 800 


Gln Val Thr Phe Phe Phe Pro Leu Asp Leu Ser Tyr Arg Lys Val Ser 
                805                 810                 815     


Thr Leu Gln Asn Gln Arg Ser Gln Arg Ser Trp Arg Leu Ala Cys Glu 
            820                 825                 830         


Ser Ala Ser Ser Thr Glu Val Ser Gly Ala Leu Lys Ser Thr Ser Cys 
        835                 840                 845             


Ser Ile Asn His Pro Ile Phe Pro Glu Asn Ser Glu Val Thr Phe Asn 
    850                 855                 860                 


Ile Thr Phe Asp Val Asp Ser Lys Ala Ser Leu Gly Asn Lys Leu Leu 
865                 870                 875                 880 


Leu Lys Ala Asn Val Thr Ser Glu Asn Asn Met Pro Arg Thr Asn Lys 
                885                 890                 895     


Thr Glu Phe Gln Leu Glu Leu Pro Val Lys Tyr Ala Val Tyr Met Val 
            900                 905                 910         


Val Thr Ser His Gly Val Ser Thr Lys Tyr Leu Asn Phe Thr Ala Ser 
        915                 920                 925             


Glu Asn Thr Ser Arg Val Met Gln His Gln Tyr Gln Val Ser Asn Leu 
    930                 935                 940                 


Gly Gln Arg Ser Leu Pro Ile Ser Leu Val Phe Leu Val Pro Val Arg 
945                 950                 955                 960 


Leu Asn Gln Thr Val Ile Trp Asp Arg Pro Gln Val Thr Phe Ser Glu 
                965                 970                 975     


Asn Leu Ser Ser Thr Cys His Thr Lys Glu Arg Leu Pro Ser His Ser 
            980                 985                 990         


Asp Phe Leu Ala Glu Leu Arg Lys  Ala Pro Val Val Asn  Cys Ser Ile 
        995                 1000                 1005             


Ala Val  Cys Gln Arg Ile Gln  Cys Asp Ile Pro Phe  Phe Gly Ile 
    1010                 1015                 1020             


Gln Glu  Glu Phe Asn Ala Thr  Leu Lys Gly Asn Leu  Ser Phe Asp 
    1025                 1030                 1035             


Trp Tyr  Ile Lys Thr Ser His  Asn His Leu Leu Ile  Val Ser Thr 
    1040                 1045                 1050             


Ala Glu  Ile Leu Phe Asn Asp  Ser Val Phe Thr Leu  Leu Pro Gly 
    1055                 1060                 1065             


Gln Gly  Ala Phe Val Arg Ser  Gln Thr Glu Thr Lys  Val Glu Pro 
    1070                 1075                 1080             


Phe Glu  Val Pro Asn Pro Leu  Pro Leu Ile Val Gly  Ser Ser Val 
    1085                 1090                 1095             


Gly Gly  Leu Leu Leu Leu Ala  Leu Ile Thr Ala Ala  Leu Tyr Lys 
    1100                 1105                 1110             


Leu Gly  Phe Phe Lys Arg Gln  Tyr Lys Asp Met Met  Ser Glu Gly 
    1115                 1120                 1125             


Gly Pro  Pro Gly Ala Glu Pro  Gln 
    1130                 1135     


<210>  36
<211>  747
<212>  PRT
<213>  Homo sapiens


<220>
<221>  CHAIN
<222>  (1)..(747)
<223>  Human Itgb2; positions 23 to 769 of Uniprot ID P05107.2

<400>  36

Gln Glu Cys Thr Lys Phe Lys Val Ser Ser Cys Arg Glu Cys Ile Glu 
1               5                   10                  15      


Ser Gly Pro Gly Cys Thr Trp Cys Gln Lys Leu Asn Phe Thr Gly Pro 
            20                  25                  30          


Gly Asp Pro Asp Ser Ile Arg Cys Asp Thr Arg Pro Gln Leu Leu Met 
        35                  40                  45              


Arg Gly Cys Ala Ala Asp Asp Ile Met Asp Pro Thr Ser Leu Ala Glu 
    50                  55                  60                  


Thr Gln Glu Asp His Asn Gly Gly Gln Lys Gln Leu Ser Pro Gln Lys 
65                  70                  75                  80  


Val Thr Leu Tyr Leu Arg Pro Gly Gln Ala Ala Ala Phe Asn Val Thr 
                85                  90                  95      


Phe Arg Arg Ala Lys Gly Tyr Pro Ile Asp Leu Tyr Tyr Leu Met Asp 
            100                 105                 110         


Leu Ser Tyr Ser Met Leu Asp Asp Leu Arg Asn Val Lys Lys Leu Gly 
        115                 120                 125             


Gly Asp Leu Leu Arg Ala Leu Asn Glu Ile Thr Glu Ser Gly Arg Ile 
    130                 135                 140                 


Gly Phe Gly Ser Phe Val Asp Lys Thr Val Leu Pro Phe Val Asn Thr 
145                 150                 155                 160 


His Pro Asp Lys Leu Arg Asn Pro Cys Pro Asn Lys Glu Lys Glu Cys 
                165                 170                 175     


Gln Pro Pro Phe Ala Phe Arg His Val Leu Lys Leu Thr Asn Asn Ser 
            180                 185                 190         


Asn Gln Phe Gln Thr Glu Val Gly Lys Gln Leu Ile Ser Gly Asn Leu 
        195                 200                 205             


Asp Ala Pro Glu Gly Gly Leu Asp Ala Met Met Gln Val Ala Ala Cys 
    210                 215                 220                 


Pro Glu Glu Ile Gly Trp Arg Asn Val Thr Arg Leu Leu Val Phe Ala 
225                 230                 235                 240 


Thr Asp Asp Gly Phe His Phe Ala Gly Asp Gly Lys Leu Gly Ala Ile 
                245                 250                 255     


Leu Thr Pro Asn Asp Gly Arg Cys His Leu Glu Asp Asn Leu Tyr Lys 
            260                 265                 270         


Arg Ser Asn Glu Phe Asp Tyr Pro Ser Val Gly Gln Leu Ala His Lys 
        275                 280                 285             


Leu Ala Glu Asn Asn Ile Gln Pro Ile Phe Ala Val Thr Ser Arg Met 
    290                 295                 300                 


Val Lys Thr Tyr Glu Lys Leu Thr Glu Ile Ile Pro Lys Ser Ala Val 
305                 310                 315                 320 


Gly Glu Leu Ser Glu Asp Ser Ser Asn Val Val Gln Leu Ile Lys Asn 
                325                 330                 335     


Ala Tyr Asn Lys Leu Ser Ser Arg Val Phe Leu Asp His Asn Ala Leu 
            340                 345                 350         


Pro Asp Thr Leu Lys Val Thr Tyr Asp Ser Phe Cys Ser Asn Gly Val 
        355                 360                 365             


Thr His Arg Asn Gln Pro Arg Gly Asp Cys Asp Gly Val Gln Ile Asn 
    370                 375                 380                 


Val Pro Ile Thr Phe Gln Val Lys Val Thr Ala Thr Glu Cys Ile Gln 
385                 390                 395                 400 


Glu Gln Ser Phe Val Ile Arg Ala Leu Gly Phe Thr Asp Ile Val Thr 
                405                 410                 415     


Val Gln Val Leu Pro Gln Cys Glu Cys Arg Cys Arg Asp Gln Ser Arg 
            420                 425                 430         


Asp Arg Ser Leu Cys His Gly Lys Gly Phe Leu Glu Cys Gly Ile Cys 
        435                 440                 445             


Arg Cys Asp Thr Gly Tyr Ile Gly Lys Asn Cys Glu Cys Gln Thr Gln 
    450                 455                 460                 


Gly Arg Ser Ser Gln Glu Leu Glu Gly Ser Cys Arg Lys Asp Asn Asn 
465                 470                 475                 480 


Ser Ile Ile Cys Ser Gly Leu Gly Asp Cys Val Cys Gly Gln Cys Leu 
                485                 490                 495     


Cys His Thr Ser Asp Val Pro Gly Lys Leu Ile Tyr Gly Gln Tyr Cys 
            500                 505                 510         


Glu Cys Asp Thr Ile Asn Cys Glu Arg Tyr Asn Gly Gln Val Cys Gly 
        515                 520                 525             


Gly Pro Gly Arg Gly Leu Cys Phe Cys Gly Lys Cys Arg Cys His Pro 
    530                 535                 540                 


Gly Phe Glu Gly Ser Ala Cys Gln Cys Glu Arg Thr Thr Glu Gly Cys 
545                 550                 555                 560 


Leu Asn Pro Arg Arg Val Glu Cys Ser Gly Arg Gly Arg Cys Arg Cys 
                565                 570                 575     


Asn Val Cys Glu Cys His Ser Gly Tyr Gln Leu Pro Leu Cys Gln Glu 
            580                 585                 590         


Cys Pro Gly Cys Pro Ser Pro Cys Gly Lys Tyr Ile Ser Cys Ala Glu 
        595                 600                 605             


Cys Leu Lys Phe Glu Lys Gly Pro Phe Gly Lys Asn Cys Ser Ala Ala 
    610                 615                 620                 


Cys Pro Gly Leu Gln Leu Ser Asn Asn Pro Val Lys Gly Arg Thr Cys 
625                 630                 635                 640 


Lys Glu Arg Asp Ser Glu Gly Cys Trp Val Ala Tyr Thr Leu Glu Gln 
                645                 650                 655     


Gln Asp Gly Met Asp Arg Tyr Leu Ile Tyr Val Asp Glu Ser Arg Glu 
            660                 665                 670         


Cys Val Ala Gly Pro Asn Ile Ala Ala Ile Val Gly Gly Thr Val Ala 
        675                 680                 685             


Gly Ile Val Leu Ile Gly Ile Leu Leu Leu Val Ile Trp Lys Ala Leu 
    690                 695                 700                 


Ile His Leu Ser Asp Leu Arg Glu Tyr Arg Arg Phe Glu Lys Glu Lys 
705                 710                 715                 720 


Leu Lys Ser Gln Trp Asn Asn Asp Asn Pro Leu Phe Lys Ser Ala Thr 
                725                 730                 735     


Thr Thr Val Met Asn Pro Lys Phe Ala Glu Ser 
            740                 745         


<210>  37
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  human alphaM integrin peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(19)

<400>  37

Arg Pro Gln Val Thr Phe Ser Glu Asn Leu Ser Ser Thr Cys His Thr 
1               5                   10                  15      


Lys Glu Arg 
            


<210>  38
<211>  186
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Catalytic domain of human MT4-MMP (hrMT4-MMP)


<220>
<221>  MISC_FEATURE
<222>  (1)..(186)

<400>  38

Gln Ala Pro Ala Pro Thr Lys Trp Asn Lys Arg Asn Leu Ser Trp Arg 
1               5                   10                  15      


Val Arg Thr Phe Pro Arg Asp Ser Pro Leu Gly His Asp Thr Val Arg 
            20                  25                  30          


Ala Leu Met Tyr Tyr Ala Leu Lys Val Trp Ser Asp Ile Ala Pro Leu 
        35                  40                  45              


Asn Phe His Glu Val Ala Gly Ser Ala Ala Asp Ile Gln Ile Asp Phe 
    50                  55                  60                  


Ser Lys Ala Asp His Asn Asp Gly Tyr Pro Phe Asp Gly Pro Gly Gly 
65                  70                  75                  80  


Thr Val Ala His Ala Phe Phe Pro Gly His His His Thr Ala Gly Asp 
                85                  90                  95      


Thr His Phe Asp Asp Asp Glu Ala Trp Thr Phe Arg Ser Ser Asp Ala 
            100                 105                 110         


His Gly Met Asp Leu Phe Ala Val Ala Val His Glu Phe Gly His Ala 
        115                 120                 125             


Ile Gly Leu Ser His Val Ala Ala Ala His Ser Ile Met Arg Pro Tyr 
    130                 135                 140                 


Tyr Gln Gly Pro Val Gly Asp Pro Leu Arg Tyr Gly Leu Pro Tyr Glu 
145                 150                 155                 160 


Asp Lys Val Arg Val Trp Gln Leu Tyr Gly Val Arg Glu Ser Val Ser 
                165                 170                 175     


Pro Thr Ala Gln Pro Glu Glu Pro Pro Leu 
            180                 185     


<210>  39
<211>  434
<212>  PRT
<213>  Mus musculus


<220>
<221>  CHAIN
<222>  (1)..(134)
<223>  full-length mouse (mus musculus) MMP17 mature protein; positions 
       125-558 of Uniprot ID: Q9R0S3, July 27, 2011 - v3

<400>  39

Gln Thr Pro Pro Pro Thr Lys Trp Ser Lys Arg Asn Leu Ser Trp Arg 
1               5                   10                  15      


Val Arg Thr Phe Pro Arg Asp Ser Pro Leu Gly Arg Asp Thr Val Arg 
            20                  25                  30          


Ala Leu Met Tyr Tyr Ala Leu Lys Val Trp Ser Asp Ile Thr Pro Leu 
        35                  40                  45              


Asn Phe His Glu Val Ala Gly Asn Ala Ala Asp Ile Gln Ile Asp Phe 
    50                  55                  60                  


Ser Lys Ala Asp His Asn Asp Gly Tyr Pro Phe Asp Gly Pro Gly Gly 
65                  70                  75                  80  


Thr Val Ala His Ala Phe Phe Pro Gly Asp His His Thr Ala Gly Asp 
                85                  90                  95      


Thr His Phe Asp Asp Asp Glu Pro Trp Thr Phe Arg Ser Ser Asp Ala 
            100                 105                 110         


His Gly Met Asp Leu Phe Ala Val Ala Val His Glu Phe Gly His Ala 
        115                 120                 125             


Ile Gly Leu Ser His Val Ala Ala Pro Ser Ser Ile Met Gln Pro Tyr 
    130                 135                 140                 


Tyr Gln Gly Pro Val Gly Asp Pro Leu Arg Tyr Gly Leu Pro Tyr Glu 
145                 150                 155                 160 


Asp Arg Val Arg Val Trp Gln Leu Tyr Gly Val Arg Glu Ser Val Ser 
                165                 170                 175     


Pro Thr Ala Gln Leu Asp Thr Pro Glu Pro Glu Glu Pro Pro Leu Leu 
            180                 185                 190         


Pro Glu Pro Pro Asn Asn Arg Ser Ser Thr Pro Pro Gln Lys Asp Val 
        195                 200                 205             


Pro His Arg Cys Thr Ala His Phe Asp Ala Val Ala Gln Ile Arg Gly 
    210                 215                 220                 


Glu Ala Phe Phe Phe Lys Gly Lys Tyr Phe Trp Arg Leu Thr Arg Asp 
225                 230                 235                 240 


Arg His Leu Val Ser Leu Gln Pro Ala Gln Met His Arg Phe Trp Arg 
                245                 250                 255     


Gly Leu Pro Leu His Leu Asp Ser Val Asp Ala Val Tyr Glu Arg Thr 
            260                 265                 270         


Ser Asp His Lys Ile Val Phe Phe Lys Gly Asp Arg Tyr Trp Val Phe 
        275                 280                 285             


Lys Asp Asn Asn Val Glu Glu Gly Tyr Pro Arg Pro Val Ser Asp Phe 
    290                 295                 300                 


Ser Leu Pro Pro Gly Gly Ile Asp Ala Val Phe Ser Trp Ala His Asn 
305                 310                 315                 320 


Asp Arg Thr Tyr Phe Phe Lys Asp Gln Leu Tyr Trp Arg Tyr Asp Asp 
                325                 330                 335     


His Thr Arg Arg Met Asp Pro Gly Tyr Pro Ala Gln Gly Pro Leu Trp 
            340                 345                 350         


Arg Gly Val Pro Ser Met Leu Asp Asp Ala Met Arg Trp Ser Asp Gly 
        355                 360                 365             


Ala Ser Tyr Phe Phe Arg Gly Gln Glu Tyr Trp Lys Val Leu Asp Gly 
    370                 375                 380                 


Glu Leu Glu Ala Ala Pro Gly Tyr Pro Gln Ser Thr Ala Arg Asp Trp 
385                 390                 395                 400 


Leu Val Cys Gly Glu Pro Leu Ala Asp Ala Glu Asp Val Gly Pro Gly 
                405                 410                 415     


Pro Gln Gly Arg Ser Gly Ala Gln Asp Gly Leu Ala Val Cys Ser Cys 
            420                 425                 430         


Thr Ser 
        


<210>  40
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LEM-3 immunogenic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(22)

<400>  40

Cys Ala His Ser Ile Met Arg Pro Tyr Tyr Gln Gly Pro Val Gly Asp 
1               5                   10                  15      


Pro Leu Arg Tyr Gly Cys 
            20          


<210>  41
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acids 137-156 of the mature human MT4-MMP (SEQ ID NO: 34)


<220>
<221>  MISC_FEATURE
<222>  (1)..(20)

<400>  41

Ala His Ser Ile Met Arg Pro Tyr Tyr Gln Gly Pro Val Gly Asp Pro 
1               5                   10                  15      


Leu Arg Tyr Gly 
            20  


<210>  42
<211>  298
<212>  PRT
<213>  Homo sapiens


<220>
<221>  CHAIN
<222>  (1)..(298)
<223>  Human mature osteopontin; pos 17-314 of Uniprot ID P10451,  July 
       1, 1989 - v1

<400>  42

Ile Pro Val Lys Gln Ala Asp Ser Gly Ser Ser Glu Glu Lys Gln Leu 
1               5                   10                  15      


Tyr Asn Lys Tyr Pro Asp Ala Val Ala Thr Trp Leu Asn Pro Asp Pro 
            20                  25                  30          


Ser Gln Lys Gln Asn Leu Leu Ala Pro Gln Asn Ala Val Ser Ser Glu 
        35                  40                  45              


Glu Thr Asn Asp Phe Lys Gln Glu Thr Leu Pro Ser Lys Ser Asn Glu 
    50                  55                  60                  


Ser His Asp His Met Asp Asp Met Asp Asp Glu Asp Asp Asp Asp His 
65                  70                  75                  80  


Val Asp Ser Gln Asp Ser Ile Asp Ser Asn Asp Ser Asp Asp Val Asp 
                85                  90                  95      


Asp Thr Asp Asp Ser His Gln Ser Asp Glu Ser His His Ser Asp Glu 
            100                 105                 110         


Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala Thr Glu 
        115                 120                 125             


Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly 
    130                 135                 140                 


Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg 
145                 150                 155                 160 


Pro Asp Ile Gln Tyr Pro Asp Ala Thr Asp Glu Asp Ile Thr Ser His 
                165                 170                 175     


Met Glu Ser Glu Glu Leu Asn Gly Ala Tyr Lys Ala Ile Pro Val Ala 
            180                 185                 190         


Gln Asp Leu Asn Ala Pro Ser Asp Trp Asp Ser Arg Gly Lys Asp Ser 
        195                 200                 205             


Tyr Glu Thr Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His Ser His 
    210                 215                 220                 


Lys Gln Ser Arg Leu Tyr Lys Arg Lys Ala Asn Asp Glu Ser Asn Glu 
225                 230                 235                 240 


His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser Arg Glu 
                245                 250                 255     


Phe His Ser His Glu Phe His Ser His Glu Asp Met Leu Val Val Asp 
            260                 265                 270         


Pro Lys Ser Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile Ser His 
        275                 280                 285             


Glu Leu Asp Ser Ala Ser Ser Glu Val Asn 
    290                 295             


<210>  43
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  "In silico 1": In silico identified epitope corresponding to 
       positions 137-156 of MT4-MMP (SEQ ID NO:34)


<220>
<221>  MISC_FEATURE
<222>  (1)..(8)

<400>  43

Val Arg Glu Ser Val Ser Pro Thr 
1               5               


<210>  44
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  "In silico 2": In silico identified epitope corresponding to 
       positions 171-178 of MT4-MMP (SEQ ID NO:34)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  44

Ala Asp His Asn Asp Gly Tyr Pro Phe Asp 
1               5                   10  


<210>  45
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  "In silico 3": In silico identified epitope corresponding to 
       positions 86-95 of MT4-MMP (SEQ ID NO:34)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  45

Phe Phe Pro Gly His His His Thr Ala Gly 
1               5                   10  


<210>  46
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  "In silico 4": In silico identified epitope corresponding to 
       positions 1-11 of MT4-MMP (SEQ ID NO:34)


<220>
<221>  MISC_FEATURE
<222>  (1)..(11)

<400>  46

Gln Ala Pro Ala Pro Thr Lys Trp Asn Lys Arg 
1               5                   10      


<210>  47
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  N-terminal fragment of SEQ ID NO:37 (Cleaved peptide)


<220>
<221>  MISC_FEATURE
<222>  (1)..(8)

<400>  47

Arg Pro Gln Val Thr Ser Glu Asn 
1               5               


<210>  48
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (24A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  48

Gln Ser Val Val Gln Leu Gln Gly Ser Arg 
1               5                   10  


<210>  49
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (37A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  49

Gly Ala Pro Gln Glu Ile Val Ala Ala Asn 
1               5                   10  


<210>  50
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (42A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  50

Ile Val Ala Ala Asn Gln Arg Gly Ser Leu 
1               5                   10  


<210>  51
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (61A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  51

Cys Glu Pro Ile Arg Leu Gln Val Pro Val 
1               5                   10  


<210>  52
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (70A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  52

Val Glu Ala Val Asn Met Ser Leu Gly Leu 
1               5                   10  


<210>  53
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (85A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  53

Thr Ser Pro Pro Gln Leu Leu Ala Cys Gly 
1               5                   10  


<210>  54
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (86A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  54

Ser Pro Pro Gln Leu Leu Ala Cys Gly Pro 
1               5                   10  


<210>  55
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (113A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  55

Leu Phe Gly Ser Asn Leu Arg Gln Gln Pro 
1               5                   10  


<210>  56
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (124A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  56

Lys Phe Pro Glu Ala Leu Arg Gly Cys Pro 
1               5                   10  


<210>  57
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (137A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  57

Ser Asp Ile Ala Phe Leu Ile Asp Gly Ser 
1               5                   10  


<210>  58
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (162A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  58

Ser Thr Val Met Glu Gln Leu Lys Lys Ser 
1               5                   10  


<210>  59
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (163A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  59

Thr Val Met Glu Gln Leu Lys Lys Ser Lys 
1               5                   10  


<210>  60
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (172A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  60

Lys Thr Leu Phe Ser Leu Met Gln Tyr Ser 
1               5                   10  


<210>  61
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (173A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  61

Thr Leu Phe Ser Leu Met Gln Tyr Ser Glu 
1               5                   10  


<210>  62
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (175A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  62

Phe Ser Leu Met Gln Tyr Ser Glu Glu Phe 
1               5                   10  


<210>  63
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (197A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  63

Pro Asn Pro Arg Ser Leu Val Lys Pro Ile 
1               5                   10  


<210>  64
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (203A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  64

Val Lys Pro Ile Thr Gln Leu Leu Gly Arg 
1               5                   10  


<210>  65
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (204A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  65

Lys Pro Ile Thr Gln Leu Leu Gly Arg Thr 
1               5                   10  


<210>  66
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (224A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  66

Arg Glu Leu Phe Asn Ile Thr Asn Gly Ala 
1               5                   10  


<210>  67
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (235A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  67

Lys Asn Ala Phe Lys Ile Leu Val Val Ile 
1               5                   10  


<210>  68
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (304A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  68

Asn Asn Phe Glu Ala Leu Lys Thr Ile Gln 
1               5                   10  


<210>  69
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (310A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  69

Lys Thr Ile Gln Asn Gln Leu Arg Glu Lys 
1               5                   10  


<210>  70
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (311A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  70

Thr Ile Gln Asn Gln Leu Arg Glu Lys Ile 
1               5                   10  


<210>  71
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (342A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  71

Gly Phe Ser Ala Ala Ile Thr Ser Asn Gly 
1               5                   10  


<210>  72
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (348A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  72

Thr Ser Asn Gly Pro Leu Leu Ser Thr Val 
1               5                   10  


<210>  73
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (350A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  73

Asn Gly Pro Leu Leu Ser Thr Val Gly Ser 
1               5                   10  


<210>  74
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (364A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  74

Gly Gly Val Phe Leu Tyr Thr Ser Lys Glu 
1               5                   10  


<210>  75
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (375A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  75

Ser Thr Phe Ile Asn Met Thr Arg Val Asp 
1               5                   10  


<210>  76
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (393A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  76

Gly Tyr Ala Ala Ala Ile Ile Leu Arg Asn 
1               5                   10  


<210>  77
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (402A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  77

Asn Arg Val Gln Ser Leu Val Leu Gly Ala 
1               5                   10  


<210>  78
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (417A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  78

Ile Gly Leu Val Ala Met Phe Arg Gln Asn 
1               5                   10  


<210>  79
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (418A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  79

Gly Leu Val Ala Met Phe Arg Gln Asn Thr 
1               5                   10  


<210>  80
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (420A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  80

Val Ala Met Phe Arg Gln Asn Thr Gly Met 
1               5                   10  


<210>  81
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (507A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  81

Arg Phe Gly Ala Ala Leu Thr Val Leu Gly 
1               5                   10  


<210>  82
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (537A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  82

Arg Gly Ala Val Tyr Leu Phe His Gly Thr 
1               5                   10  


<210>  83
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (552A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  83

Ser Pro Ser His Ser Gln Arg Ile Ala Gly 
1               5                   10  


<210>  84
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (581A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  84

Leu Thr Met Asp Gly Leu Val Asp Leu Thr 
1               5                   10  


<210>  85
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (584A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  85

Asp Gly Leu Val Asp Leu Thr Val Gly Ala 
1               5                   10  


<210>  86
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (589A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  86

Leu Thr Val Gly Ala Gln Gly His Val Leu 
1               5                   10  


<210>  87
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (595A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  87

Gly His Val Leu Leu Leu Arg Ser Gln Pro 
1               5                   10  


<210>  88
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (606A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  88

Leu Arg Val Lys Ala Ile Met Glu Phe Asn 
1               5                   10  


<210>  89
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (690A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  89

Thr Gln Val Leu Gly Leu Thr Gln Thr Cys 
1               5                   10  


<210>  90
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (699A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  90

Cys Glu Thr Leu Lys Leu Gln Leu Pro Asn 
1               5                   10  


<210>  91
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (712A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  91

Asp Pro Val Ser Pro Ile Val Leu Arg Leu 
1               5                   10  


<210>  92
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (716A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  92

Pro Ile Val Leu Arg Leu Asn Phe Ser Leu 
1               5                   10  


<210>  93
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (720A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  93

Arg Leu Asn Phe Ser Leu Val Gly Thr Pro 
1               5                   10  


<210>  94
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (731A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  94

Ser Ala Phe Gly Asn Leu Arg Pro Val Leu 
1               5                   10  


<210>  95
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (742A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  95

Glu Asp Ala Gln Arg Leu Phe Thr Ala Leu 
1               5                   10  


<210>  96
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (772A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  96

Phe Ser Phe Met Ser Leu Asp Cys Leu Val 
1               5                   10  


<210>  97
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (775A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  97

Met Ser Leu Asp Cys Leu Val Val Gly Gly 
1               5                   10  


<210>  98
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (809A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  98

Phe Phe Pro Leu Asp Leu Ser Tyr Arg Lys 
1               5                   10  


<210>  99
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (817A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  99

Arg Lys Val Ser Thr Leu Gln Asn Gln Arg 
1               5                   10  


<210>  100
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (820A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  100

Ser Thr Leu Gln Asn Gln Arg Ser Gln Arg 
1               5                   10  


<210>  101
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (828A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  101

Gln Arg Ser Trp Arg Leu Ala Cys Glu Ser 
1               5                   10  


<210>  102
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (842A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  102

Glu Val Ser Gly Ala Leu Lys Ser Thr Ser 
1               5                   10  


<210>  103
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (910A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  103

Lys Tyr Ala Val Tyr Met Val Val Thr Ser 
1               5                   10  


<210>  104
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (943A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  104

Tyr Gln Val Ser Asn Leu Gly Gln Arg Ser 
1               5                   10  


<210>  105
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (952A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  105

Ser Leu Pro Ile Ser Leu Val Phe Leu Val 
1               5                   10  


<210>  106
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (955A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  106

Ile Ser Leu Val Phe Leu Val Pro Val Arg 
1               5                   10  


<210>  107
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (960A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  107

Leu Val Pro Val Arg Leu Asn Gln Thr Val 
1               5                   10  


<210>  108
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (977A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  108

Thr Phe Ser Glu Asn Leu Ser Ser Thr Cys 
1               5                   10  


<210>  109
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (997A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  109

Asp Phe Leu Ala Glu Leu Arg Lys Ala Pro 
1               5                   10  


<210>  110
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1030A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  110

Glu Phe Asn Ala Thr Leu Lys Gly Asn Leu 
1               5                   10  


<210>  111
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1048A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  111

Ser His Asn His Leu Leu Ile Val Ser Thr 
1               5                   10  


<210>  112
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1064A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  112

Asp Ser Val Phe Thr Leu Leu Pro Gly Gln 
1               5                   10  


<210>  113
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1122B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  113

Gly Asp Pro Asp Ser Ile Arg Cys Asp Thr 
1               5                   10  


<210>  114
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1131B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  114

Thr Arg Pro Gln Leu Leu Met Arg Gly Cys 
1               5                   10  


<210>  115
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1132B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  115

Arg Pro Gln Leu Leu Met Arg Gly Cys Ala 
1               5                   10  


<210>  116
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1146B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  116

Met Asp Pro Thr Ser Leu Ala Glu Thr Gln 
1               5                   10  


<210>  117
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1163B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  117

Lys Gln Leu Ser Pro Gln Lys Val Thr Leu 
1               5                   10  


<210>  118
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1165B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  118

Leu Ser Pro Gln Lys Val Thr Leu Tyr Leu 
1               5                   10  


<210>  119
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1169B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  119

Lys Val Thr Leu Tyr Leu Arg Pro Gly Gln 
1               5                   10  


<210>  120
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1177B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  120

Gly Gln Ala Ala Ala Phe Asn Val Thr Phe 
1               5                   10  


<210>  121
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1191B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  121

Gly Tyr Pro Ile Asp Leu Tyr Tyr Leu Met 
1               5                   10  


<210>  122
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1194B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  122

Ile Asp Leu Tyr Tyr Leu Met Asp Leu Ser 
1               5                   10  


<210>  123
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1197B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  123

Tyr Tyr Leu Met Asp Leu Ser Tyr Ser Met 
1               5                   10  


<210>  124
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1201B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  124

Asp Leu Ser Tyr Ser Met Leu Asp Asp Leu 
1               5                   10  


<210>  125
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1205B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  125

Ser Met Leu Asp Asp Leu Arg Asn Val Lys 
1               5                   10  


<210>  126
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1211B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  126

Arg Asn Val Lys Lys Leu Gly Gly Asp Leu 
1               5                   10  


<210>  127
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1219B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  127

Asp Leu Leu Arg Ala Leu Asn Glu Ile Thr 
1               5                   10  


<210>  128
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1249B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  128

Thr His Pro Asp Lys Leu Arg Asn Pro Cys 
1               5                   10  


<210>  129
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1266B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  129

Gln Pro Pro Phe Ala Phe Arg His Val Leu 
1               5                   10  


<210>  130
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1272B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  130

Arg His Val Leu Lys Leu Thr Asn Asn Ser 
1               5                   10  


<210>  131
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1286B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  131

Thr Glu Val Gly Lys Gln Leu Ile Ser Gly 
1               5                   10  


<210>  132
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1292B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  132

Leu Ile Ser Gly Asn Leu Asp Ala Pro Glu 
1               5                   10  


<210>  133
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1302B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  133

Gly Gly Leu Asp Ala Met Met Gln Val Ala 
1               5                   10  


<210>  134
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1304B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  134

Leu Asp Ala Met Met Gln Val Ala Ala Cys 
1               5                   10  


<210>  135
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1320B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  135

Arg Asn Val Thr Arg Leu Leu Val Phe Ala 
1               5                   10  


<210>  136
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1340B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  136

Gly Lys Leu Gly Ala Ile Leu Thr Pro Asn 
1               5                   10  


<210>  137
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1369B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  137

Pro Ser Val Gly Gln Leu Ala His Lys Leu 
1               5                   10  


<210>  138
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1373B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  138

Gln Leu Ala His Lys Leu Ala Glu Asn Asn 
1               5                   10  


<210>  139
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1388B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  139

Ala Val Thr Ser Arg Met Val Lys Thr Tyr 
1               5                   10  


<210>  140
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1395B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  140

Lys Thr Tyr Glu Lys Leu Thr Glu Ile Ile 
1               5                   10  


<210>  141
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1407B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  141

Ser Ala Val Gly Glu Leu Ser Glu Asp Ser 
1               5                   10  


<210>  142
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1417B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  142

Ser Asn Val Val Gln Leu Ile Lys Asn Ala 
1               5                   10  


<210>  143
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1418B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  143

Asn Val Val Gln Leu Ile Lys Asn Ala Tyr 
1               5                   10  


<210>  144
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1440B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  144

Ala Leu Pro Asp Thr Leu Lys Val Thr Tyr 
1               5                   10  


<210>  145
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1486B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  145

Glu Cys Ile Gln Glu Gln Ser Phe Val Ile 
1               5                   10  


<210>  146
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1590B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  146

Asp Val Pro Gly Lys Leu Ile Tyr Gly Gln 
1               5                   10  


<210>  147
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1694B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  147

Ser Cys Ala Glu Cys Leu Lys Phe Glu Lys 
1               5                   10  


<210>  148
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1713B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  148

Ala Cys Pro Gly Leu Gln Leu Ser Asn Asn 
1               5                   10  


<210>  149
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1765A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  149

Pro Asn Pro Leu Pro Leu Ile Val Gly Ser 
1               5                   10  


<210>  150
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1774A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  150

Ser Ser Val Gly Gly Leu Leu Leu Leu Ala 
1               5                   10  


<210>  151
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1777A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  151

Gly Gly Leu Leu Leu Leu Ala Leu Ile Thr 
1               5                   10  


<210>  152
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1779A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  152

Leu Leu Leu Leu Ala Leu Ile Thr Ala Ala 
1               5                   10  


<210>  153
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1780A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  153

Leu Leu Leu Ala Leu Ile Thr Ala Ala Leu 
1               5                   10  


<210>  154
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1784A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  154

Leu Ile Thr Ala Ala Leu Tyr Lys Leu Gly 
1               5                   10  


<210>  155
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1785A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  155

Ile Thr Ala Ala Leu Tyr Lys Leu Gly Phe 
1               5                   10  


<210>  156
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1787A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  156

Ala Ala Leu Tyr Lys Leu Gly Phe Phe Lys 
1               5                   10  


<210>  157
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1817B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  157

Pro Asn Ile Ala Ala Ile Val Gly Gly Thr 
1               5                   10  


<210>  158
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1833B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  158

Ile Gly Ile Leu Leu Leu Val Ile Trp Lys 
1               5                   10  


<210>  159
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1842B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  159

Lys Ala Leu Ile His Leu Ser Asp Leu Arg 
1               5                   10  


<210>  160
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  predicted cleavage site of the human alphaMbeta2 integrin (1845B)


<220>
<221>  MISC_FEATURE
<222>  (1)..(10)

<400>  160

Ile His Leu Ser Asp Leu Arg Glu Tyr Arg 
1               5                   10  


